Fennec Pharmaceuticals Inc. — 10-Q Summary
Filing identity discrepancy: The supplied filing is for Adherex Technologies Inc., not Fennec Pharmaceuticals Inc. The summary below reflects the filing text provided. It covers the unaudited quarter ended March 31, 2012; amounts are in U.S. dollars, generally in thousands unless stated otherwise.
Business context and reporting period
Adherex describes itself as a development-stage biopharmaceutical company focused on cancer therapeutics. Its programs include eniluracil, in a Phase II trial, and STS, being studied in collaborator-managed Phase III trials. The company reported no revenue.
Key financial metrics
| Metric | Q1 2012 / March 31, 2012 | Comparable period / December 31, 2011 |
|---|---|---|
| Revenue | $0 | $0 in Q1 2011 |
| Operating expenses | $616 | $1,021 in Q1 2011 |
| Operating loss | $(616) | $(1,021) in Q1 2011 |
| Net income | $2,715 | $4,669 in Q1 2011 |
| Derivative gain | $3,327, non-cash | $5,680 in Q1 2011 |
| Cash and cash equivalents | $4,719 | $5,297 at December 31, 2011 |
| Cash used in operating activities | $578 | $1,048 in Q1 2011 |
| Total assets / total liabilities | $4,757 / $2,162 | $5,351 / $5,471 at December 31, 2011 |
| Working capital, excluding derivative liabilities | $4,345 | $4,957 at December 31, 2011 |
Reported net income was principally attributable to the $3.3 million unrealized gain from remeasuring warrant and other derivative liabilities; it did not represent operating cash generation. No debt balance or interest expense is reported for the quarter. Profit margins are not meaningful because the company had no revenue.
Material changes versus the prior comparable period
- Net income fell by $1.954 million year over year, mainly as the derivative gain declined by $2.353 million.
- Operating expenses decreased by $405,000: research and development was $296,000 versus $315,000, and general and administrative expense was $320,000 versus $706,000. The filing attributes the G&A decrease largely to expenses related to the March 2011 rights offering.
- Operating cash use improved by $470,000 year over year. Cash decreased by $578,000 from year-end, which management attributed to clinical-trial and administrative costs.
- Derivative liabilities declined to $1.750 million from $5.077 million at year-end, primarily reflecting fair-value remeasurement. Stockholders’ equity rose from a $120,000 deficiency to $2.595 million.
Outlook, risks, contingencies and unusual items
- Going concern: Management states that substantial doubt exists about the company’s ability to continue as a going concern. It needs additional funding through equity, debt, collaborations, licensing or other sources; without it, the company may curtail or discontinue activities.
- Clinical outlook: As of May 10, 2012, the eniluracil Phase II trial had enrolled 114 patients, with full enrollment of approximately 140 expected in Q3 2012. The company reported 131 patients enrolled in the Children’s Oncology Group STS trial and 53 in the SIOPEL trial. These are forward-looking expectations and trial progress, not assurances of success.
- Funding and development risk: The company says it lacks the financial and human resources to complete future Phase III trials independently and is seeking development partners. Clinical, regulatory, commercialization and financing outcomes remain uncertain.
- Commitments: Contractual obligations totaled $514,000, including $478,000 due in less than one year, primarily for clinical-trial services and drug purchases.
- Derivative valuation: Warrant liabilities are measured using a Black-Scholes model and are sensitive to assumptions including volatility and remaining term. Fair-value gains and losses can materially affect reported earnings without affecting cash until exercise.
- Controls: Management concluded disclosure controls were not effective and identified two material weaknesses: inadequate segregation of accounting duties and insufficient technical U.S. GAAP accounting expertise. The filing says remediation depends partly on obtaining additional resources.
- Other: The company reported no legal proceedings, material off-balance-sheet arrangements, or material capital-expenditure commitments. It also cited penny-stock trading restrictions and potential Toronto Stock Exchange listing-standard risk.
Important facts for investors to verify
- Confirm the issuer: the supplied 10-Q names Adherex Technologies Inc., not Fennec Pharmaceuticals Inc.
- Assess available financing and cash runway in light of the explicit going-concern warning and continued operating cash use.
- Verify subsequent enrollment, trial milestones and funding or collaboration developments for eniluracil and STS.
- Review the assumptions and sensitivity of the $1.750 million derivative liability and its impact on reported earnings.
- Check whether the disclosed internal-control material weaknesses were subsequently remediated.
- Confirm share-count and potential dilution information: 25.158 million common shares outstanding, plus 18.035 million warrant shares and 5.134 million options reported as outstanding.